227 results on '"Montanaro, Marco"'
Search Results
2. Using knowledge graphs for audio retrieval: a case study on copyright infringement detection
3. Using Focused Crawlers with Obfuscation Techniques in the Audio Retrieval Domain
4. Nursing Management of Frail Patients with Hematologic Malignancies During COVID-19 Pandemia in the Viterbo Domiciliary Care Unit: Data Analysis from March 2020 to March 2021
5. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
6. A rule-based obfuscating focused crawler in the audio retrieval domain
7. Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting
8. Fibrin-associated large B-cell lymphoma: first case report within a cerebral artery aneurysm and literature review
9. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN
10. Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis
11. Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events
12. Domiciliary Nursing Management for Patients Affected By Multiple Myeloma during Covid-19 Pandemia in the Viterbo Home Care Unit: Data Analysis from March 2020 to March 2022
13. Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases
14. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
15. Nursing Management of Frail Patients with Hematologic Malignancies during COVID-19 Pandemia in the Viterbo Domiciliary Care Unit: Data Analysis from March 2020 to March 2021
16. Azacytidine Treatment in Patients with Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome: Day-Hospital Management Compared to Home Care Setting
17. Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase
18. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients
19. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
20. Data Protection and Data Commerce: Friends or Foes?
21. Symptomatic Mucocutaneous Toxicity of Hydroxyurea in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: The Mister Hyde Face of a Safe Drug
22. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience
23. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1‐negative Myeloproliferative Neoplasms Latium Group”
24. Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
25. High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients
26. Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events
27. Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up
28. IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy
29. Fibrin-Associated Large B-Cell Lymphoma: First Case Report Within A Cerebral Artery Aneurysm And Literature Review
30. Fibrin-Associated Large B-Cell Lymphoma: First Report Within A Cerebral Artery Aneurysm And Literature Review
31. Treatment of Philadelphia‐negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors
32. Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?
33. Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region
34. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia
35. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia
36. Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN
37. The Neutrophil/Lymphocyte Ratio (N/L) Is a Prognostic Marker in Patients with Diffuse Large B Cell Lymphoma: A Prospective Study from the Lazio Lymphoma Registry
38. Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN)
39. Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN
40. Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis
41. Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis
42. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
43. Subcutaneous Daratumumab at Home Is a Safe and Effective Procedure for Frail Patients with Multiple Myeloma: A Myelhome Project Report
44. Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms
45. The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients
46. Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?
47. Treatment of Myeloproliferative Neoplasms in Blastic Phase with Azacytidine. Clinical Results and Identification of Prognostic Factors
48. Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase
49. The Experience of Gruppo Laziale for the Study of Ph-, Chronic Myeloproliferative Syndromes in the Treatment of Myeloproliferative Neoplasms in Blastic Phase with Azacytidine
50. Hematological Improvement during Deferasirox Treatment in Patients with Myeloproliferative Neoplasms (MPN)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.